Effects of competitive and non-competitive NMDA receptor antagonists on behavioral responses induced by 7-OH-DPAT and quinpirole in rats

Pharmacological Research

Volumn 36, Issue 3, 1997, Pages 203-209

  Dall'Olio, Rossella ^a   Rimondini, Roberto ^a   Gandolfi, Ottavio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

7 OH DPAT; CGP 43487; D3 and D2 receptors; Dizocilpine; Locomotor activity; Quinpirole; Stereotyped behaviour

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; DIZOCILPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; QUINPIROLE; RADIOLIGAND;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; INTRAPERITONEAL DRUG ADMINISTRATION; LIGAND BINDING; LOCOMOTION; MALE; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOTYPY;

EID: 0031236939     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1997.0223     Document Type: Article

References (42)

1. 1. Dawbarn D, Pycock CJ. Motor effects following application of putative excitatory amino acid antagonists to the region of the mesencephalic dopamine cell bodies in the rat. Naunyn-Schmiedeberg's Arch Pharmacol 1981; 318: 100-4.
2. 2. Chapman CD, Gazzara RA, Howard SG. Effects of phencyclidine on extracellular levels of dopamine, dihydro-phenylacetic acid and homovanillic acid in conscious and anesthetized rats. Neuropharmacology 1990; 29: 319-25.
3. 3. Imperato A, Scrocco MG, Bacchi S, Angelucci L. NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur J Pharmacol 1990; 187: 555-6
4. 4. Kabuto H, Yokoi I, Mizukawa K, Mori A. Effects of an JV-methyl-D-aspartate receptor agonist and its antagonists CPP on the levels of dopamine and serotonin metabolites in rat striatum collected in vivo by using a brain dialysis technique. Neurochem Res 1989; 14: 1075-80.
5. 5. Liljequist S, Ossowska K, Grabowska-Anden M, Anden NE. Effect of the NMDA receptor antagonist, MK 801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice. Eur J Pharmacol 1991; 195: 55-61.
6. 6. Gandolfi O, Rimondini R, Dall'Olio R. The modulation of dopaminergic transmission in the striatum by MK 801 is independent of presynaptic mechanisms. Neuropharmacology 1992; 31: 1111-4.
7. 7. Verma A, Kulkarni SK. Modulation of MK 801 response by dopaminergic agents in mice. Psychopharmacology 1992; 107: 431-6.
8. 2 receptor-dependent locomotion by glutamate antagonists in reserpine-treated mouse. Eur J Pharmacol 1993; 250: 239-46.
9. 1 receptor mechanisms in the potentiation of motor responses to L-DOPA and apomorphine by MK 801 in the reserpine-treated mouse. J Neural Transm [P-D Sect] 1994; 8: 107-16.
10. 10. Dall'Olio R, Rimondini R, Gandolfi O. The competitive NMDA antagonists CGP 43487 and APV potentiate dopaminergic function. Psychopharmacology 1995; 118: 310-15.
11. 2 mediated behaviours in intact rats. Psychopharmacology 1996; 123: 187-90.
12. 12. Dall'Olio R, Gandolfi O, Montanaro N. Effect of chronic treatment with dizocilpine (MK-801) on the behavioural response to dopamine receptor agonists in the rat. Psychopharmacology 1992; 107: 591-4.
13. 13. Liljequist S. Genetic differences in the effects of competitive and non-competitive NMDA receptor antagonists on locomotor activity in mice. Psychopharmacology 1991; 104: 17-21.
14. 14. Starr MS, Starr BS. The new competitive NMDA receptor antagonist CGP 40116 inhibits pilocarpine-induced limbic motor seizures and unconditioned motor behaviour in the mouse. Pharmacol Biochem Behav 1994; 47: 127-31.
15. 2 dopamine agonists in reserpine-treated mice. Psychopharmacology 1994; 114: 469-76.
16. 3) as a target for neuroleptics. Nature 1990; 347: 146-51.
17. 2-like' agonists. Neuropharmacology 1993; 32: 509-10.
18. 3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. J Neural Transm [Gen Sect] 1994; 95: 71-4.
19. 3 receptors. Eur J Pharmacol 1994; 263: 235-43.
20. 3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat. Eur J Pharmacol 1994; 260: 177-81.
21. 3 receptor: Chinese hamster or Chinese whispers? Trends Pharmacol Sci 1994; 15: 46-7.
22. 3 dopamine receptors. Neuropsychopharmacology 1995; 12: 335-45.
23. 2 as well as D3 receptors. Eur J Pharmacol 1995; 272: R1-R3.
24. 3H]-hydroxy-N,N,di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 1992; 89: 8155-9.
25. 2 dopamine receptors. Mol Pharmacol 1994; 45: 51-60.
26. 3 receptors: effects of ions and guanine nucleotides. J Pharmacol Exp Ther 1995; 274: 791-7.
27. 27. Robbins TW. A critique of the methods available for the measurement of spontaneous motor activity. In: Iversen LL, Iversen SD, Snyder SH, eds. Handbook of Psychopharmacology, vol 7. New York: Plenum Press, 1977: pp. 37-82.
28. 1 supersensitive rats. Psychopharmacology 1988; 95: 381-5.
29. 3H]-Spiroperidol on rat striatal membranes. Eur J Pharmacol 1978; 50: 283-4.
30. 3H]propyl-2-aminotetralin and carbetapentane. J Neurochem 1995; 64: 700-10.
31. 31. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.
32. 3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology 1996; 124: 231-40.
33. 3-receptor: a post-synaptic receptor inhibitory on rat locomotor activity. J. Neural Transm [Gen. Sect.] 1993; 94: 11-19.
34. 34. Timmerman W, Tepper PG, Dijkstra D, Stoelwinder H, Grol CJ, Westerink BHC, Horn AS. Enantiomers of monohydroxy-2-aminotetralin derivatives and their activity at dopamine autoreceptors as studies by brain dialysis. Eur J Pharmacol 1991; 199: 145-51.
35. 35. Damsma G, Bottema T, Westerink BHC, Tepper PG, Dijkstra D, Pugsley TA, MacKenzie RG, Heffner TG, Wilkstrom H. Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. Eur J Pharmacol 1993; 249: R9-R10.
36. 36. Gilbert DB, Millar J, Cooper SJ. The putative D3 agonist, 7-OH-DPAT, reduces dopamine release in the nucleus accumbens and electical self-stimulation to the ventral tegmentum. Brain Res 1995; 681: 1-7.
37. 3 receptors and sigma sites in the bovine caudate nucleus. Eur J Pharmacol 1993; 242: R1-R2.
38. 38. Maurice T, Hiramatsu M, Itoh J, Kameyama T, Hasegawa T, Nabeshima T. Low dose of 1,3-di(2-Tolyl)guanidine (DTG) attenuates MK-801-induced spatial working memory impairment in mice. Psychopharmacology 1994; 114: 520-2.
39. 39. Maurice T, Su TP, Parish DW, Nabeshima T, Privat A. PRE-084, a sigma selective PCP derivative, attenuates MK-801-induced impairment of learning in mice. Pharmacol Biochem Behav 1994; 49: 859-69.
40. 40. Debonnel G, De Montigny C. Modulation of NMDA and dopaminergic neurotransmission by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci 1996; 58: 721-34.
41. 41. Ernst AM. Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacologia 1967; 10: 316-23.
42. 42. Ljungberg T, Ungerstedt U. Apomorphine-induced locomotion and gnawing: evidence that the experimental design greately influences gnawing while locomotion remain unchanged. Eur J Pharmacol 1977; 46: 147-51.